These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 558266

  • 1. On the origin of urinary fibrin-fibrinogen-related antigen in glomerulonephritis.
    Bone JM, Sherman LA, Valdes AJ, Lubowitz H.
    J Lab Clin Med; 1977 May; 89(5):1043-52. PubMed ID: 558266
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [ Products of fibrin degradation in the urine during experimental and human glomerulonephritis].
    Lagrue G, Hirbec G, Gouault-Heilmann M, Levent M, Branellec A, Moisy M.
    Pathol Biol (Paris); 1975 Jun; 23(6):486-91. PubMed ID: 1105353
    [Abstract] [Full Text] [Related]

  • 4. [Significance of urinary fibrin/fibrinogen degradation products (FDP) measured by highly sensitive ELISA method in various renal diseases].
    Shibata T, Sumie A, Ishii T, Tomo T, Magari Y, Sato J, Yasumori R, Nasu M.
    Nihon Jinzo Gakkai Shi; 1993 Jun; 35(6):687-94. PubMed ID: 8377281
    [Abstract] [Full Text] [Related]

  • 5. [Monoclonal antibodies against fibrinogen and fibrin and against their proteolytic degradation products].
    Dyr JE, Cajthamlová H, Suttnar J.
    Cas Lek Cesk; 1990 Oct 26; 129(43):1349-51. PubMed ID: 2249231
    [Abstract] [Full Text] [Related]

  • 6. Significance of urinary excretion of fibrin degradation products during treatment of glomerulonephritis.
    Michielsen P, Roels L, Vanrenterghem Y, Boel A, van Damme B, Vermylen J.
    Clin Nephrol; 1976 Mar 26; 5(3):105-13. PubMed ID: 1261101
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Specific identification of urinary fibrinogen, fibrinogen degradation products, and cross-linked fibrin degradation products in renal diseases and after renal allotransplantation.
    Scott WL, Francis CW, Knutson DW, Marder VJ.
    J Lab Clin Med; 1986 Jun 26; 107(6):534-43. PubMed ID: 3519810
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Urinary fibrinogen degradation products and differential protein clearances in renal disease.
    Blainey JD, Terry JM.
    Clin Nephrol; 1979 Mar 26; 11(3):140-1. PubMed ID: 436342
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Sequential studies of glomerular crescent formation in rats with antiglomerular basement membrane-induced glomerulonephritis and the role of coagulation factors.
    Silva FG, Hoyer JR, Pirani CL.
    Lab Invest; 1984 Oct 26; 51(4):404-15. PubMed ID: 6434880
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Enhanced glomerular procoagulant activity and fibrin deposition in rats with mercuric chloride-induced autoimmune nephritis.
    Kanfer A, de Prost D, Guettier C, Nochy D, Le Floch V, Hinglais N, Druet P.
    Lab Invest; 1987 Aug 26; 57(2):138-43. PubMed ID: 3475499
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Fibrinolysis in glomerulonephritis treated with ancrod: renal functional, immunologic and histopathologic effects.
    Kim S, Wadhwa NK, Kant KS, Pollak VE, Glas-Greenwalt P, Weiss MA, Hong CG.
    Q J Med; 1988 Nov 26; 69(259):879-905. PubMed ID: 3078212
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.